Related Experiment Videos
Increased macrophage colony-stimulating factor levels in immune thrombocytopenic purpura
Z R Zeigler1, C S Rosenfeld, J J Nemunaitis
1Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh 15224.
Abstract:
Thrombocytopenia is a dose-limiting toxicity of macrophage colony-stimulating factor (M-CSF) in preclinical and initial phase I trials. Modulation of macrophage-mediated platelet destruction in immune thrombocytopenic purpura (ITP) may be affected by M-CSF activity. In this study, plasma levels of M-CSF were determined by a sensitive radioimmunoassay in 23 patients with ITP. These were compared with control levels measured in 24 healthy subjects. M-CSF levels were significantly higher in the ITP patients than in the control subjects (218 v 179, P < .02); however, there was a great deal of overlap. The highest M-CSF levels (median = 299 U/mL) were observed in three patients with Evan's syndrome. Patients with severe ITP (platelets < 25,000/microL) had intermediate M-CSF levels (median = 231 U/mL) and those with mild thrombocytopenia (> 25,000/microL) had normal levels (median = 173 U/mL). Sixteen patients were treated with corticosteroids: 10 responded and 6 did not. Median M-CSF levels were higher in those who failed to respond compared with responders (272 v 202, P < .05). These findings suggest M-CSF may influence macrophage-mediated platelet destruction in ITP.
Insights
Macrophage colony-stimulating factor (M-CSF) levels are elevated in immune thrombocytopenic purpura (ITP) patients, particularly those with severe disease or poor response to corticosteroids. This suggests M-CSF may play a role in platelet destruction in ITP.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Thrombocytopenia, a decrease in platelet count, is a known toxicity of macrophage colony-stimulating factor (M-CSF).
- Macrophage activity is implicated in platelet destruction in immune thrombocytopenic purpura (ITP).
Purpose of the Study:
- To investigate plasma levels of M-CSF in patients with ITP.
- To determine the correlation between M-CSF levels and ITP severity and treatment response.
Main Methods:
- Plasma M-CSF levels were measured using radioimmunoassay in 23 ITP patients and 24 healthy controls.
- M-CSF levels were compared between patient groups based on disease severity and corticosteroid treatment outcomes.
Main Results:
- ITP patients exhibited significantly higher M-CSF levels than healthy subjects (218 vs 179 U/mL, P < .02).
- Elevated M-CSF levels were observed in severe ITP and in patients who did not respond to corticosteroids.
- Highest M-CSF levels were found in patients with Evan's syndrome.
Conclusions:
- M-CSF levels are elevated in ITP patients, suggesting a potential role in the pathogenesis of the disease.
- M-CSF may influence macrophage-mediated platelet destruction in ITP, particularly in non-responders to corticosteroid therapy.